Eupraxia Adds Three Pharma Veterans to Board, Bolstering Commercialization Expertise
EPRX sits 29% above its 52-week low of $4.88.
Summary
Eupraxia Pharmaceuticals appointed Robert Bazemore, Amy Pott, and Dr. Helen Thackray to its Board of Directors. These new members bring extensive experience in late-stage drug development, commercial strategy, and global product launches. This move strengthens the company's leadership at a pivotal stage, following recent positive Phase 1b/2a trial data for EP-104GI and a new Chief Medical Officer appointment in May. The added expertise is critical as Eupraxia prepares for potential commercialization and pipeline expansion.
At the time of this announcement, EPRX was trading at $6.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.9M. The 52-week trading range was $4.88 to $9.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.